









Markets
/
Stocks
/
nasdaq-clls
/

Cellectis SA

CLLS

View Detailed Chart

2.950USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

212.68MMarket Cap

LossP/E TTM



Cellectis SA

2.950

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

+17.53%

5 Days

+17.06%

1 Month

+86.71%

6 Months

+89.10%

Year to Date

+63.89%

1 Year

+41.15%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 6 analysts

BUY

Current Rating

5.667

Target Price

92.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Cellectis SA

CLLS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(0)

Neutral(2)

Buy(10)

Indicators

Sell(0)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.153

Buy

RSI(14)

69.222

Neutral

STOCH(KDJ)(9,3,3)

76.343

Neutral

ATR(14)

0.344

Low Volatility

CCI(14)

111.730

Buy

Williams %R

11.278

Overbought

TRIX(12,20)

2.456

Buy

StochRSI(14)

61.057

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.757

Buy

MA10

2.432

Buy

MA20

2.120

Buy

MA50

1.723

Buy

MA100

1.559

Buy

MA200

1.636

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Ticker SymbolCLLS

CompanyCellectis SA

CEODr. David Sourdive, Ph.D.

Websitehttps://www.cellectis.com/